DataMeds AI, Inc. MEDS
Other Pharmaceuticals · IPO 2025 · data as of November 13, 2026
DataMeds AI, Inc. (MEDS) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $8M and net income of -$43M, a net margin of -564.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -311%.
About DataMeds AI
DataMeds AI is listed in the US and classified in other pharmaceuticals, IPO year 2025. It was profitable in 0 of the last 3 years in our data.
Score: 0.6 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $8M | $23M | $18M | — |
| Net income | -$43M | -$101M | -$7M | -$3M |
| Free cash flow | -$16M | -$11M | -$1M | -$349136 |
| EPS (diluted) | $-9.16 | $-21.45 | $-2.25 | $-0.90 |
| Net margin | -564.8% | -433.9% | -37.8% | — |
| ROIC | — | -606.8% | -15.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does DataMeds AI pay a dividend?
Not currently.
Is DataMeds AI a good stock to buy?
We do not give buy or sell advice. DataMeds AI scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.